Abstract: There is provided a method and apparatus for identifying malicious code. The method uses machine learning to compare a new code segment to known code segments of malicious code. Code segments are converted to vectors and the cosine similarity of two vectors is used to identify clones. Techniques to train a neural network for handling very long code sequences and obfuscated malicious code are used.

Abstract: A piece of luggage including a main body and a power supplying module is disclosed. The main body includes a moving module including a plurality of wheels and a main motor and a power unit electrically connected to the moving module. The wheels include an active wheel electrically connected to the main motor. The power supplying module includes a power supplying unit including a power supplying box and a battery and a connecting unit including a connecting part, a holding part and a conducting wire. The power supplying box has an output port. The battery is disposed in the power supplying box and electrically connected to the output port. The connecting part has a power port corresponding to the output port. The holding part and the conducting wire are connected to the connecting part. The conducting wire is electrically connected to the power port and the power unit.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: Methods and apparatuses are described for automatic refinement of intent classification for virtual assistant applications. A computing device creates utterance groups comprising messages. The device determines, using a first machine learning (ML) classifier, a first predicted intent associated with each utterance group and determines, using a second ML classifier, a second predicted intent associated with each utterance group. The device combines the first and second predicted intents to generate a final predicted intent, determines, for each incomprehensible utterance group, whether the final predicted intent overlaps with the final predicted intent for other utterance groups, and selects messages having no overlapping intent to create new intents.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: The disclosure relates to a system and method for controlling lamplight by using music, and an in-vehicle infotainment system. The system comprises: a music analysis unit, configured to analyze rhythm and content of music; and a lamplight control unit, configured to dynamically control, on the basis of the analysis of the rhythm and content of the music, at least one of color, brightness and variation rhythm of the color and brightness of lamplight emitted by light-emitting components. Embodiments of the present invention can achieve better integration between lamplight, music and scenes, so that a user obtains an improved acousto-optic experience.

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: A corner transition module includes a module case, a LED PCB board, a curved face cover. The LED PCB board is set in the space defined between the module case and the curved face cover. The module case is mounted on a LED installing position. A plurality of LED installing holes is provided on the curved face cover to couple with the LEDs on the LED PCB board. The corner transition module solves the problem that two flat display screens being angularly connected in resulting in a display defects with a black line at the connecting corner. With the corner transition module, the non-planar screens are seamlessly connected to form a perfect full-screen display effect in high-performance graphics display without any black line.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Abstract: A method and apparatus for pulse interference suppression, and a computer readable storage medium in a communication system are provided in the embodiments of the present invention. The method includes: judging a location where pulse interference occurs according to a power of a signal; and performing suppression processing on a data segment interfered by a pulse in the location. After judging that the pulse interference exists in the location, a receiver in the communication system discards the data segment interfered by the pulse in the location, and feeds back an indication that the data are not received.

Abstract: The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Abstract: The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF?) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.